CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Tesamorelin vs CJC 1295 No DAC: Research Comparison

Real Peptides Research TeamEditorial

Updated September 30, 202610 min read

60 WORDS

Short answer

Most write-ups on these two compounds open with potency. That's the wrong starting point. The decisive fact in the CJC 1295 no DAC vs tesamorelin question is that tesamorelin is a full-length GHRH analog with a published human clinical record and an approved drug counterpart, while CJC-1295 without DAC is a 29-amino-acid fragment that was never the molecule the original…

Key takeaways

Tesamorelin and CJC-1295 both act as GHRH receptor agonists on anterior pituitary somatotrophs, so neither supplies exogenous growth hormone and both remain under somatostatin and IGF-1 feedback control.
CJC-1295 no DAC is pharmacologically Modified GRF (1-29) with a half-life around 30 minutes, while CJC-1295 with DAC was reported at 5.8 to 8.1 days in the 2006 JCEM pharmacokinetic study.
Tesamorelin is the only compound in this comparison with phase 3 human endpoint data, reporting visceral adipose tissue reductions on the order of 15% over roughly six months with subcutaneous fat largely unchanged.
Applying published CJC-1295 data to a no-DAC vial is the single most common analytical error in this comparison, because the literature studied the albumin-bound version.
Neither compound has been established as a muscle-building agent; reported lean mass changes on GHRH analogs are modest and confounded by GH-driven fluid shifts.
Anecdotal comparisons circulating on forums lack purity verification, blinding and imaging endpoints, which makes them unusable as evidence in either direction.

We supply both compounds to research laboratories, and we get asked to settle this roughly every week. Our answer hasn't changed: they answer different research questions. The labs that generate clean, reproducible data are the ones that pick based on the endpoint they're measuring, not on which peptide has the louder reputation.

Which is better in the CJC 1295 no DAC vs tesamorelin comparison?

Neither compound is universally better. Tesamorelin carries the stronger human evidence base, including an approved drug counterpart (Egrifta) indicated for HIV-associated visceral adipose tissue. CJC-1295 no DAC is a short-acting GHRH fragment with a half-life measured in minutes, used to model pulsatile growth hormone release. The research endpoint decides the compound.

The most common error here is treating CJC-1295 as one compound. It isn't. The DAC and no-DAC forms differ by roughly three orders of magnitude in circulating half-life, which means an honest comparison has to be three-way, not two-way. What follows covers the receptor pharmacology both molecules share, why the 'no DAC' label creates a citation trap that skews half the discussions online, and what the lipolysis, IGF-1 and lean mass literature actually reports for each.

Both compounds hit the same receptor. Almost nothing else matches.

Tesamorelin and CJC-1295 are both GHRH (growth hormone releasing hormone) analogs, meaning they bind GHRHR, the class B G protein coupled receptor sitting on somatotroph cells in the anterior pituitary. Binding raises intracellular cAMP and triggers release of growth hormone the pituitary has already synthesised, which then acts on hepatic GH receptors to drive IGF-1 (insulin-like growth factor 1) output. Neither compound supplies exogenous growth hormone, and both remain subject to the body's existing brakes: somatostatin tone and IGF-1 negative feedback.

Structure is where they part company. CJC-1295 without DAC is GRF(1-29) carrying four amino acid substitutions: D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27. The D-Ala2 swap blocks cleavage by DPP-4 (dipeptidyl peptidase-4), the serum enzyme that degrades native GHRH within minutes. Reported half-life still sits in the region of half an hour.

Attach the DAC (Drug Affinity Complex) and the pharmacokinetics change category, not degree. The maleimidopropionyl linker forms a covalent bond with circulating serum albumin, converting the peptide into a slow-release depot. Teichman and colleagues, publishing in the Journal of Clinical Endocrinology and Metabolism in 2006, reported a terminal half-life of 5.8 to 8.1 days in healthy adults, with growth hormone elevated for several days and IGF-1 elevated for longer still after a single administration.

Tesamorelin takes a third route. It is the full 44-amino-acid human GRF sequence with a trans-3-hexenoyl group bonded to the N-terminal tyrosine, a modification that also resists DPP-4 while leaving the half-life short, in the range of tens of minutes. In our experience, half the confusion in this comparison clears the moment researchers see those three half-lives lined up next to each other.

The no-DAC naming trap that skews half this comparison

Here's the part most comparisons miss entirely. The compound published as CJC-1295 in the peer-reviewed literature was the DAC version. The vial labelled 'CJC-1295 no DAC' is pharmacologically Modified GRF (1-29), a name that came out of the research-peptide market rather than the group that developed the original molecule. So when someone pulls CJC-1295 data from a database and applies it to a no-DAC vial, they are importing multi-day pharmacokinetics onto a compound that clears in under an hour. That single mismatch explains a large share of the contradictory protocol write-ups circulating online.

This matters for tesamorelin vs CJC 1295 without DAC in a very specific way. A short-acting GHRH analog produces a discrete GH pulse that rises and decays, which is what somatotroph physiology does on its own. Continuous receptor occupancy behaves differently: it flattens pulsatility and gives somatostatin tone and rising IGF-1 time to blunt subsequent responses. If a model depends on pulse amplitude, pulse frequency or trough recovery between stimulations, tesamorelin and CJC-1295 no DAC behave like siblings and the DAC version behaves like a different class of tool altogether.

Which reframes the whole question. Tesamorelin vs CJC 1295 with DAC is not really a potency contest; it's a choice between pulsatile and tonic GHRHR stimulation. Our team has reviewed enough incoming protocol questions to see the pattern clearly: researchers who state their pulsatility requirement first almost never end up comparing the wrong two compounds.

What the lipolysis, IGF-1 and lean mass literature actually reports

Tesamorelin has the deeper human record by a wide margin. It is the active ingredient in Egrifta, which holds regulatory approval for reduction of excess abdominal fat in people with HIV-associated lipodystrophy. The trial program supporting that approval reported reductions in visceral adipose tissue on the order of 15% measured by CT over roughly six months, with subcutaneous fat largely unchanged. That compartment selectivity is the detail worth noticing, because it separates a GHRH effect on visceral fat depots from general weight loss. Subsequent research has examined liver fat and cognitive endpoints. Research-grade tesamorelin supplied to laboratories is not an approved drug product and is not for human or animal administration.

CJC-1295 no DAC has nothing comparable. What exists is mechanistic rather than outcome-based: GRF(1-29) analogs reliably provoke GH release and, with repeated stimulation, raise IGF-1. Controlled human data on fat compartments, lean mass or hepatic fat simply isn't there, and any comparison that implies otherwise is filling a gap with inference.

On tesamorelin vs CJC 1295 for muscle growth, the honest position is that neither compound has been established as a hypertrophy agent. GHRH analogs act upstream on the GH and IGF-1 axis, and the lean body mass changes reported in tesamorelin research were modest and accompanied by the fluid retention that is a well-documented consequence of raising GH. Mechanical loading and protein availability remain the variables that move contractile tissue.

This article is research education rather than guidance for personal use. Compounds supplied for laboratory research are not for human consumption, and anyone weighing a GHRH analog for a companion animal should talk to their veterinarian instead of sourcing research material.

CJC 1295 no DAC vs tesamorelin: side-by-side research comparison

This table separates the three molecules people conflate in this debate. Read the half-life row first, because every downstream difference follows from it.

Attribute	CJC-1295 no DAC (Mod GRF 1-29)	CJC-1295 with DAC	Tesamorelin	Bottom Line
Structure	GRF(1-29) with four substitutions, including D-Ala2 for DPP-4 resistance	Same 29-mer plus a maleimidopropionyl linker that binds serum albumin	Full 44-amino-acid human GRF with an N-terminal trans-3-hexenoyl group	Chain length and the albumin linker, not potency, drive every practical difference
Reported half-life	Around 30 minutes	Reported at 5.8 to 8.1 days in healthy adults	Short, in the range of tens of minutes	The DAC form is the outlier; the other two are pharmacokinetically comparable
GH release pattern	Discrete pulse that rises and decays	Sustained, largely non-pulsatile elevation	Discrete pulse closer to native GHRH signalling	Pulsatile models should exclude the DAC form from the start
Human clinical evidence	Mechanistic GH and IGF-1 data only, no outcome trials	Single-dose pharmacokinetic and IGF-1 data in healthy adults	Phase 3 program in HIV-associated lipodystrophy, plus liver fat and cognition research	Tesamorelin is the only one of the three with hard clinical endpoint data
Regulatory status	Not an approved drug in any jurisdiction	Not an approved drug in any jurisdiction	Approved as Egrifta for a specific indication; research-grade material is not an approved product	Approval attaches to the finished drug, never to research-grade powder
Typical research cost	Lower, reflecting a shorter and simpler synthesis	Mid-range, with added linker chemistry	Higher, reflecting a 44-residue chain plus N-terminal modification	Price tracks synthesis difficulty, so unusually cheap tesamorelin deserves scrutiny

What If: Research Scenarios Labs Actually Face

What if the model only needs sustained IGF-1, not pulsatile GH?

The DAC form becomes the logical candidate and tesamorelin becomes the harder fit. Albumin binding keeps the peptide in circulation for days, which is why the published pharmacokinetic work reported prolonged IGF-1 elevation after a single administration. A short-acting analog would require repeated stimulation to approximate the same exposure profile, introducing timing variables that complicate the data set. Choose based on exposure curve, not on which compound sounds stronger.

What if forum threads report the opposite of the published literature?

Treat tesamorelin vs CJC 1295 Reddit results as hypothesis generation, never as evidence. Those reports typically lack third-party purity testing, blinding, controlled nutrition, and any imaging endpoint such as CT or DEXA, so what gets described as a compound difference is often a difference in diet, training or vial quality. Reported IGF-1 numbers are also drawn at inconsistent intervals, which matters enormously when one compound peaks in hours and the other over days.

What if a lab wants to compare the two on lean mass endpoints?

Build the design around measurement before choosing the peptide. Without body composition imaging that separates lean tissue from fluid, GH-driven water retention will contaminate any lean mass signal on either compound. Tesamorelin at least has prior human data to anchor expectations; CJC-1295 no DAC does not, so a comparison on hypertrophy endpoints is exploratory work rather than replication of anything published.

What if a vial arrives shipped warm or without a certificate of analysis?

Quarantine it and request the batch documentation before reconstituting anything. Lyophilised GHRH analogs are reasonably tolerant of brief ambient exposure in powder form, but potency and purity claims are unverifiable without third-party HPLC and mass spectrometry results tied to that specific lot. A vial with no traceable certificate is an unknown input, and an unknown input invalidates the comparison you were trying to run.

The honest verdict most comparisons avoid

Let's be direct about this: tesamorelin has the better evidence, and CJC-1295 no DAC has the better price. That's the whole trade. If a research question involves visceral fat compartments, hepatic fat or anything requiring a documented human precedent, tesamorelin is the defensible choice and nothing in the CJC-1295 literature substitutes for it. If the question is about pulsatile GHRHR signalling mechanics and budget matters, the no-DAC fragment does that job at a fraction of the synthesis cost. Anyone claiming one compound is simply superior is comparing marketing copy, not pharmacology.

Researchers sourcing either molecule can review our CJC-1295 No DAC and Tesamorelin listings, compare related compounds across the growth hormone secretagogue collection and the muscle growth and recovery research range, and pull batch-level certificates of analysis before committing a study design to either compound.

The CJC 1295 no DAC vs tesamorelin debate keeps circling because people are comparing three molecules while using two names. Sort the nomenclature first, and the pharmacology stops being contradictory: one 44-residue analog with clinical endpoint data, one 29-residue fragment that models a natural pulse, and one albumin-bound depot that does something neither of the others can. Pick the exposure curve your endpoint requires, verify the lot, and the comparison answers itself.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Tesamorelin has the stronger evidence base, with phase 3 human data and an approved drug counterpart for HIV-associated visceral fat. CJC-1295 no DAC is cheaper and models pulsatile GH release but lacks outcome trials. Better depends entirely on whether the research endpoint requires clinical precedent or pulse mechanics.

For documented clinical endpoints, tesamorelin is better because its trial program reported visceral adipose tissue reductions measured by CT. For short-acting GHRH receptor pharmacology at lower cost, CJC-1295 no DAC is the more practical tool. Neither outperforms the other across every research question, so the endpoint decides.

Neither compound is established as a muscle growth agent. Both act upstream on the GH and IGF-1 axis rather than directly on muscle tissue, and lean mass changes reported in tesamorelin research were modest and confounded by growth hormone driven fluid retention. Mechanical loading remains the primary hypertrophy variable.

CJC-1295 no DAC is a 29-amino-acid GRF fragment with four substitutions and a half-life around 30 minutes. Tesamorelin is the full 44-amino-acid human GRF sequence with a trans-3-hexenoyl group at the N-terminus. Both resist DPP-4 degradation, but only tesamorelin has phase 3 human clinical data.

They are close. Both clear quickly, with CJC-1295 no DAC reported around 30 minutes and tesamorelin in the range of tens of minutes. The dramatic outlier is CJC-1295 with DAC, reported at 5.8 to 8.1 days because the Drug Affinity Complex binds it to serum albumin.

For sustained exposure, the DAC version produces a longer IGF-1 elevation from a single administration, which the 2006 JCEM pharmacokinetic study documented in healthy adults. Tesamorelin clears too quickly to replicate that curve without repeated stimulation. The trade-off is that continuous receptor occupancy suppresses the natural pulsatility of growth hormone release.

Forum reports vary widely and split roughly along cost lines, with tesamorelin favoured for visceral fat observations and CJC-1295 no DAC for affordability. These accounts lack purity verification, blinding and imaging endpoints, so they cannot distinguish a compound effect from diet, training or a low-quality vial. Treat them as anecdote only.

Combining two GHRH receptor agonists is generally redundant because they compete for the same GHRHR binding site on pituitary somatotrophs. Research designs exploring additive effects more commonly pair a GHRH analog with a ghrelin receptor agonist such as ipamorelin, which acts through a separate pathway. Any combined design should be justified by receptor pharmacology, not stacking logic.

Tesamorelin typically costs noticeably more per vial because it is a 44-residue chain with an N-terminal acyl modification, which makes solid-phase synthesis longer and lower yielding than a 29-residue fragment. Exact pricing varies by supplier, vial size and purity grade. Tesamorelin priced near CJC-1295 levels warrants a close look at the certificate of analysis.

Published clinical work on GHRH analogs has reported injection site reactions, joint discomfort, fluid retention and changes in glucose handling, which is consistent with raising growth hormone. Long-term safety data for CJC-1295 in either form is limited compared with tesamorelin. Research-use compounds carry additional uncertainty because purity and endotoxin levels depend entirely on the supplier.

Lyophilised GHRH analog powder is normally held frozen and protected from light until reconstitution, after which the solution is refrigerated and treated as short-dated. Repeated freeze-thaw cycles degrade peptide integrity, and temperature excursions are not detectable by visual inspection. Documented storage conditions should always be checked against the batch certificate of analysis.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA